{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T18:33:35Z","timestamp":1772562815134,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"DOI":"10.1007\/s10585-026-10392-3","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T03:22:43Z","timestamp":1768792963000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The clinical trial landscape of colorectal cancer liver metastases: profile analysis and target prediction"],"prefix":"10.1007","volume":"43","author":[{"given":"Ming","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinyan","family":"Kai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuchentian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuai","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhijun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiqing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weixiong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"issue":"4_suppl","key":"10392_CR1","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1200\/jco.2016.34.4_suppl.555","volume":"34","author":"A Sveen","year":"2016","unstructured":"Sveen A, Loes IM, Alagaratnam S, Nilsen G, H\u00f8land M, Lingjaerde OC, Sorbye H, Berg KCG, Horn A, Angelsen J-H et al (2016) Intra-individual genetic heterogeneity among liver metastases in metastatic colorectal cancer. J Clin Oncol 34(4_suppl):555\u2013555","journal-title":"J Clin Oncol"},{"issue":"10458","key":"10392_CR2","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/S0140-6736(24)01595-2","volume":"404","author":"R Adam","year":"2024","unstructured":"Adam R, Piedvache C, Chiche L, Adam JP, Salam\u00e9 E, Bucur P, Cherqui D, Scatton O, Granger V, Ducreux M et al (2024) Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial. Lancet 404(10458):1107\u20131118","journal-title":"Lancet"},{"issue":"1","key":"10392_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41572-021-00261-6","volume":"7","author":"DI Tsilimigras","year":"2021","unstructured":"Tsilimigras DI, Brodt P, Clavien PA, Muschel RJ, D\u2019Angelica MI, Endo I, Parks RW, Doyle M, de Santiba\u00f1es E, Pawlik TM (2021) Liver metastases. Nat Rev Dis Primers 7(1):27","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10392_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41575-023-00841-9","volume":"21","author":"CC Murphy","year":"2024","unstructured":"Murphy CC, Zaki TA (2024) Changing epidemiology of colorectal cancer\u2014birth cohort effects and emerging risk factors. Nat Rev Gastroenterol Hepatol 21(1):25\u201334","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"10392_CR5","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1200\/JCO.21.01015","volume":"40","author":"HJ Lenz","year":"2022","unstructured":"Lenz HJ, Van Cutsem E, Luisa Limon M, Wong KYM, Hendlisz A, Aglietta M, Garc\u00eda-Alfonso P, Neyns B, Luppi G, Cardin DB et al (2022) First-line nivolumab plus low-dose Ipilimumab for microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study. J Clin Oncol 40(2):161\u2013170","journal-title":"J Clin Oncol"},{"issue":"12","key":"10392_CR6","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/s41575-019-0189-8","volume":"16","author":"N Keum","year":"2019","unstructured":"Keum N, Giovannucci E (2019) Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol 16(12):713\u2013732","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"10392_CR7","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1007\/s12072-025-10799-2","volume":"19","author":"W Zhu","year":"2025","unstructured":"Zhu W, Fan C, Zhao Y, Liu Y, Cheng Y, Zhou W (2025) Breaking bottlenecks: the future of hepatocellular carcinoma clinical trials and therapeutic targets. Hepatol Int 19(4):888\u2013902","journal-title":"Hepatol Int"},{"key":"10392_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102926","volume":"136","author":"G Bregni","year":"2025","unstructured":"Bregni G, Adams R, Bale R, Bali MA, Bargellini I, Blomqvist L, Brown G, Cremolini C, Demetter P, Denecke T et al (2025) EORTC consensus recommendations on the optimal management of colorectal cancer liver metastases. Cancer Treat Rev 136:102926","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"10392_CR9","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S2468-1253(22)00156-X","volume":"7","author":"R Qu","year":"2022","unstructured":"Qu R, Ma Y, Zhang Z, Fu W (2022) Increasing burden of colorectal cancer in China. Lancet Gastroenterol Hepatol 7(8):700","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"10392_CR10","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nrclinonc.2017.10","volume":"14","author":"Q Zhou","year":"2017","unstructured":"Zhou Q, Chen XY, Yang ZM, Wu YL (2017) The changing landscape of clinical trial and approval processes in China. Nat Rev Clin Oncol 14(9):577\u2013583","journal-title":"Nat Rev Clin Oncol"},{"key":"10392_CR11","doi-asserted-by":"crossref","unstructured":"Ellis LM (2005) Bevacizumab. Nat Rev Drug Discov (S8\u20139)","DOI":"10.1038\/nrd1727"},{"issue":"10395","key":"10392_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0140-6736(23)00772-9","volume":"402","author":"A Dasari","year":"2023","unstructured":"Dasari A, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, Sobrero A, Yao J, Garc\u00eda-Alfonso P, Kocsis J, Cubillo Gracian A et al (2023) Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet 402(10395):41\u201353","journal-title":"Lancet"},{"issue":"3","key":"10392_CR13","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40265-019-1066-z","volume":"79","author":"SM Hoy","year":"2019","unstructured":"Hoy SM (2019) Sintilimab: first global approval. Drugs 79(3):341\u2013346","journal-title":"Drugs"},{"key":"10392_CR14","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1146\/annurev-pathol-011110-130235","volume":"6","author":"ER Fearon","year":"2011","unstructured":"Fearon ER (2011) Molecular genetics of colorectal cancer. Annu Rev Pathol 6:479\u2013507","journal-title":"Annu Rev Pathol"},{"issue":"1","key":"10392_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01581-2","volume":"17","author":"W Cheng","year":"2024","unstructured":"Cheng W, Kang K, Zhao A, Wu Y (2024) Dual blockade immunotherapy targeting PD-1\/PD-L1 and CTLA-4 in lung cancer. J Hematol Oncol 17(1):54","journal-title":"J Hematol Oncol"},{"issue":"16","key":"10392_CR16","doi-asserted-by":"publisher","first-page":"e15556","DOI":"10.1200\/JCO.2022.40.16_suppl.e15556","volume":"40","author":"V Michalaki","year":"2022","unstructured":"Michalaki V, Theodosopoulos T, Frangoulidis G, Dafnios N, Papakonstantinou I, Vezakis A, Papadimitriou C (2022) Nivolumab with ipilimumab for MSI-H colorectal cancer with liver metastases. J Clin Oncol 40(16):e15556\u2013e15556","journal-title":"J Clin Oncol"},{"issue":"7756","key":"10392_CR17","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/s41586-019-1162-y","volume":"569","author":"E Perez-Ruiz","year":"2019","unstructured":"Perez-Ruiz E, Minute L, Otano I, Alvarez M, Ochoa MC, Belsue V, de Andrea C, Rodriguez-Ruiz ME, Perez-Gracia JL, Marquez-Rodas I et al (2019) Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature 569(7756):428\u2013432","journal-title":"Nature"},{"issue":"suppl_12","key":"10392_CR18","doi-asserted-by":"publisher","first-page":"xii18","DOI":"10.1093\/annonc\/mdx238","volume":"28","author":"E Lanitis","year":"2017","unstructured":"Lanitis E, Dangaj D, Irving M, Coukos G (2017) Mechanisms regulating T-cell infiltration and activity in solid tumors. Ann Oncol 28(suppl_12):xii18\u2013xii32","journal-title":"Ann Oncol"},{"issue":"9","key":"10392_CR19","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2326-6066.CIR-18-0291","volume":"6","author":"PA Beavis","year":"2018","unstructured":"Beavis PA, Henderson MA, Giuffrida L, Davenport AJ, Petley EV, House IG, Lai J, Sek K, Milenkovski N, John LB et al (2018) Dual PD-1 and CTLA-4 checkpoint blockade promotes antitumor immune responses through CD4(+)Foxp3(\u2212) cell-mediated modulation of CD103(+) dendritic cells. Cancer Immunol Res 6(9):1069\u20131081","journal-title":"Cancer Immunol Res"},{"issue":"15_suppl","key":"10392_CR20","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1200\/jco.2012.30.15_suppl.3616","volume":"30","author":"G Karagkounis","year":"2012","unstructured":"Karagkounis G, Torbenson MS, Daniel HD, Azad NS, Diaz LA, Donehower RC, Hirose K, Pawlik TM, Choti MA (2012) Incidence and prognostic impact of KRAS and BRAF mutations in patients undergoing liver surgery for colorectal metastases. J Clin Oncol 30(15_suppl):3616\u20133616","journal-title":"J Clin Oncol"},{"issue":"1","key":"10392_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-024-01865-z","volume":"10","author":"X Chen","year":"2024","unstructured":"Chen X, Ma Z, Yi Z, Wu E, Shang Z, Tuo B, Li T, Liu X (2024) The effects of metabolism on the immune microenvironment in colorectal cancer. Cell Death Discov 10(1):118","journal-title":"Cell Death Discov"},{"issue":"3","key":"10392_CR22","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/s41591-024-03443-3","volume":"31","author":"S Kopetz","year":"2025","unstructured":"Kopetz S, Yoshino T, Van Cutsem E, Eng C, Kim TW, Wasan HS, Desai J, Ciardiello F, Yaeger R, Maughan TS et al (2025) Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial. Nat Med 31(3):901\u2013908","journal-title":"Nat Med"},{"issue":"11","key":"10392_CR23","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1200\/JCO-24-01710","volume":"43","author":"KPS Raghav","year":"2025","unstructured":"Raghav KPS, Guthrie KA, Tan B Jr., Denlinger CS, Fakih M, Overman MJ, Dasari NA, Corum LR, Hicks LG, Patel MS et al (2025) Trastuzumab plus pertuzumab versus cetuximab plus irinotecan in patients with RAS\/BRAF wild-type, HER2-positive, metastatic colorectal cancer (S1613): a randomized phase II trial. J Clin Oncol 43(11):1348\u20131357","journal-title":"J Clin Oncol"},{"issue":"19","key":"10392_CR24","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1200\/JCO-24-02026","volume":"43","author":"F Pietrantonio","year":"2025","unstructured":"Pietrantonio F, Salvatore L, Esaki T, Modest DP, Lopez-Bravo DP, Taieb J, Karamouzis MV, Ruiz-Garcia E, Kim TW, Kuboki Y et al (2025) Overall survival analysis of the phase III codebreak 300 study of sotorasib plus panitumumab versus investigator\u2019s choice in chemorefractory KRAS G12C colorectal cancer. J Clin Oncol 43(19):2147\u20132154","journal-title":"J Clin Oncol"},{"issue":"2","key":"10392_CR25","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/ng.735","volume":"43","author":"K Zhou","year":"2011","unstructured":"Zhou K, Bellenguez C, Spencer CC, Bennett AJ, Coleman RL, Tavendale R, Hawley SA, Donnelly LA, Schofield C, Groves CJ et al (2011) Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet 43(2):117\u2013120","journal-title":"Nat Genet"},{"issue":"31","key":"10392_CR26","first-page":"64","volume":"16","author":"M Yi","year":"2019","unstructured":"Yi M, Xu X (2019) Correlation analysis of C11orf65 and SLC47A1 gene polymorphisms with the clinical efficacy of metformin. Chin Med Innov 16(31):64\u201369","journal-title":"Chin Med Innov"},{"issue":"16","key":"10392_CR27","first-page":"e15519","volume":"43","author":"A Nepal","year":"2025","unstructured":"Nepal A, Sudadi S, Wang H (2025) Real-world outcomes for dMMR\/MSI-H colorectal cancer navigating rapidly evolving oncologic practices in a community hospital. J Clin Oncol 43(16):e15519\u2013e15519","journal-title":"J Clin Oncol"},{"issue":"19","key":"10392_CR28","doi-asserted-by":"publisher","first-page":"5213","DOI":"10.7150\/thno.28001","volume":"8","author":"D Mai","year":"2018","unstructured":"Mai D, Ding P, Tan L, Zhang J, Pan Z, Bai R, Li C, Li M, Zhou Y, Tan W et al (2018) PIWI-interacting RNA-54265 is oncogenic and a potential therapeutic target in colorectal adenocarcinoma. Theranostics 8(19):5213\u20135230","journal-title":"Theranostics"},{"issue":"1","key":"10392_CR29","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Guti\u00e9rrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ et al (2022) Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med 386(1):24\u201334","journal-title":"N Engl J Med"},{"issue":"19","key":"10392_CR30","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1200\/JCO-24-02834","volume":"43","author":"M Shah","year":"2025","unstructured":"Shah M, Chen TY, Ison G, Fiero MH, Zhang H, Gao X, Neilson M, Goldberg KB, Nair A, Ricks TK et al (2025) Overall survival and the evolving benefit-risk assessment for poly (ADP-ribose) polymerase inhibitors in advanced ovarian cancer. J Clin Oncol 43(19):2218\u20132227","journal-title":"J Clin Oncol"},{"issue":"1","key":"10392_CR31","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.stem.2015.05.016","volume":"17","author":"Z Wu","year":"2015","unstructured":"Wu Z, Wei D, Gao W, Xu Y, Hu Z, Ma Z, Gao C, Zhu X, Li Q (2015) TPO-induced metabolic reprogramming drives liver metastasis of colorectal cancer CD110+ tumor-initiating cells. Cell Stem Cell 17(1):47\u201359","journal-title":"Cell Stem Cell"},{"issue":"4","key":"10392_CR32","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/annonc\/mdy038","volume":"29","author":"D Arnold","year":"2018","unstructured":"Arnold D, Prager GW, Quintela A, Stein A, Moreno Vera S, Mounedji N, Taieb J (2018) Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review. Ann Oncol 29(4):835\u2013856","journal-title":"Ann Oncol"},{"issue":"9","key":"10392_CR33","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1016\/j.ccell.2024.07.004","volume":"42","author":"WW Xiao","year":"2024","unstructured":"Xiao WW, Chen G, Gao YH, Lin JZ, Wu XJ, Luo HL, Lu ZH, Wang QX, Sun R, Cai PQ et al (2024) Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: a randomized clinical trial. Cancer Cell 42(9):1570\u20131581","journal-title":"Cancer Cell"},{"issue":"18","key":"10392_CR34","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1200\/JCO.19.03296","volume":"38","author":"S Fukuoka","year":"2020","unstructured":"Fukuoka S, Hara H, Takahashi N, Kojima T, Kawazoe A, Asayama M, Yoshii T, Kotani D, Tamura H, Mikamoto Y et al (2020) Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603). J Clin Oncol 38(18):2053\u20132061","journal-title":"J Clin Oncol"},{"issue":"1","key":"10392_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00449-4","volume":"6","author":"T Tang","year":"2021","unstructured":"Tang T, Huang X, Zhang G, Hong Z, Bai X, Liang T (2021) Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal Transduct Target Ther 6(1):72","journal-title":"Signal Transduct Target Ther"},{"key":"10392_CR36","doi-asserted-by":"crossref","unstructured":"Gourd K (2025) 2025 ASCO annual meeting. Lancet Oncol","DOI":"10.1016\/S1470-2045(25)00346-8"},{"issue":"11","key":"10392_CR37","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.43457","volume":"5","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Wu J, Pei F, Zhang Y, Bai S, Shi L, Zhang X, Ma J, Zhao X, Ma T et al (2022) Molecular typing and clinical characteristics of synchronous multiple primary colorectal cancer. JAMA Netw Open 5(11):e2243457","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10392_CR38","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1016\/j.apsb.2025.03.041","volume":"15","author":"H Xin","year":"2025","unstructured":"Xin H, Zhao Z, Guo S, Tian R, Ma L, Yang Y, Zhao L, Wang G, Li B, Hu X et al (2025) Targeting the JAK2-STAT3-UCHL3-ENO1 axis suppresses glycolysis and enhances the sensitivity to 5-FU chemotherapy in TP53-mutant colorectal cancer. Acta Pharm Sin B 15(5):2529\u20132544","journal-title":"Acta Pharm Sin B"},{"issue":"9","key":"10392_CR39","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/S1470-2045(17)30589-2","volume":"18","author":"HJ Schmoll","year":"2017","unstructured":"Schmoll HJ (2017) Selective internal radiotherapy in advanced colorectal cancer: only for right-sided tumours? Lancet Oncol 18(9):1138\u20131139","journal-title":"Lancet Oncol"},{"issue":"1","key":"10392_CR40","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s13046-021-02030-5","volume":"40","author":"Y Zheng","year":"2021","unstructured":"Zheng Y, Li Y, Feng J, Li J, Ji J, Wu L, Yu Q, Dai W, Wu J, Zhou Y et al (2021) Cellular based immunotherapy for primary liver cancer. J Exp Clin Cancer Res 40(1):250","journal-title":"J Exp Clin Cancer Res"},{"issue":"6220","key":"10392_CR41","doi-asserted-by":"publisher","DOI":"10.1126\/science.1260419","volume":"347","author":"M Uhl\u00e9n","year":"2015","unstructured":"Uhl\u00e9n M, Fagerberg L, Hallstr\u00f6m BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson \u00c5, Kampf C, Sj\u00f6stedt E, Asplund A et al (2015) Tissue-based map of the human proteome. Science 347(6220):1260419","journal-title":"Science"}],"container-title":["Clinical & Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-026-10392-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10585-026-10392-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-026-10392-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T16:03:55Z","timestamp":1768838635000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10585-026-10392-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["10392"],"URL":"https:\/\/doi.org\/10.1007\/s10585-026-10392-3","relation":{},"ISSN":["1573-7276"],"issn-type":[{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"19 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"10"}}